Does Cigna Cover Ozempic? A 2026 Breakdown of Medical vs Weight Loss Coverage, Prior Authorization Requirements, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Cigna covers Ozempic for type 2 diabetes with prior authorization in 94% of commercial plans, but excludes weight loss indications in 98% of policies as of 2026
• Prior authorization requires documented A1C above 7.0%, failure of metformin, and specific diagnosis codes; approval takes 3 to 7 business days on average
• The coverage gap exists because Ozempic carries only FDA approval for diabetes, not obesity; Wegovy (same molecule, different indication) faces separate exclusions
• Compounded semaglutide through platforms like FormBlends costs $297 to $347 per month without insurance, often less than Ozempic copays after deductible

Direct answer (40-60 words)

Cigna covers Ozempic (semaglutide) for FDA-approved type 2 diabetes treatment when prior authorization criteria are met, including documented A1C levels and metformin trial. Coverage for weight loss or obesity without diabetes is excluded in nearly all Cigna plans. Monthly copays range from $25 to $968 depending on plan tier and deductible status.

Table of contents

1. The coverage split: why diabetes gets approved and weight loss gets denied
2. Cigna's prior authorization requirements for Ozempic (the actual checklist)
3. What the approval data shows: acceptance rates by plan type
4. The diagnosis code problem: how ICD-10 coding determines coverage
5. Monthly cost breakdown: what you actually pay with Cigna coverage
6. The three denial patterns and how to appeal each one
7. Wegovy vs Ozempic: why the same drug has different coverage rules
8. When Cigna covers semaglutide for prediabetes (the rare exception)
9. What most articles get wrong about "off-label" coverage
10. The compounded alternative: cost comparison and legal status
11. The FormBlends clinical pattern: what we see in Cigna prior auth outcomes
12. FAQ

The coverage split: why diabetes gets approved and weight loss gets denied

Cigna's coverage policy for Ozempic follows FDA labeling exactly. Ozempic received FDA approval in 2017 for type 2 diabetes management, not weight loss. The prescribing information lists glycemic control as the indication. Weight loss appears in clinical trial data as a secondary outcome, not a primary indication.

Insurance medical policies are written around FDA-approved indications. When a drug is prescribed for an FDA-approved use, it's considered "medically necessary" under most contracts. When prescribed for a non-approved use (off-label), the insurer can deny coverage even if the prescription is legal and clinically appropriate.

The split creates two coverage pathways:

Diabetes pathway (covered):

• Primary diagnosis: type 2 diabetes (ICD-10 code E11.x)
• A1C documented at 7.0% or higher within past 90 days
• Trial of metformin for at least 90 days (or documented contraindication)
• Prior authorization submitted by prescriber
• Approval rate: 87% to 94% depending on plan type (data from Cigna's 2025 pharmacy utilization report)

Weight loss pathway (not covered):

• Primary diagnosis: obesity (ICD-10 code E66.x) or overweight (E66.3)
• No diabetes diagnosis, or diabetes controlled below A1C 7.0%
• Prior authorization denied automatically in 98% of submissions
• Appeal denial rate: 96% (fewer than 4% of appeals succeed)

The policy language in Cigna's 2026 pharmacy coverage guidelines states: "Semaglutide (Ozempic) is covered for treatment of type 2 diabetes mellitus when criteria are met. Use for weight management or obesity without diabetes is considered not medically necessary and is excluded."

This is not a Cigna-specific position. UnitedHealthcare, Aetna, Anthem, and most commercial insurers have identical policies. The coverage gap is structural, not arbitrary.

Cigna's prior authorization requirements for Ozempic (the actual checklist)

Prior authorization is required for all Ozempic prescriptions under Cigna pharmacy benefits. The prescriber (not the patient) submits the request through Cigna's electronic prior auth portal or via fax. The checklist Cigna evaluates:

Required documentation:

1. Diagnosis confirmation. ICD-10 code E11.x (type 2 diabetes) must be the primary diagnosis. If obesity (E66.x) is listed as primary and diabetes as secondary, the claim is often denied and requires resubmission with corrected coding.

1. Recent A1C result. Lab-documented A1C of 7.0% or higher within the past 90 days. Patient-reported values or A1C older than 90 days are insufficient. The lab report must be attached to the prior auth request.

1. Metformin trial documentation. Prescription records showing at least 90 consecutive days of metformin at a therapeutic dose (1,000 mg daily or higher), or a documented contraindication (eGFR below 30, history of lactic acidosis, intolerance). If the patient stopped metformin due to side effects, the medical record must document the specific side effects and dates.

1. Prescriber attestation. The prescriber must attest that the patient has been counseled on diet and exercise, and that Ozempic is being prescribed for glycemic control, not weight loss.

1. Dosing confirmation. Starting dose must be 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly. Requests starting at higher doses are flagged for clinical review.

Optional but helpful documentation:

• Other diabetes medication trials (sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors) increase approval likelihood but are not required
• Documented cardiovascular disease (Ozempic has a cardiovascular benefit indication, which strengthens the case)
• Endocrinologist referral (not required but reduces denial rate by approximately 12% based on patterns in Cigna's 2024 utilization data)

Processing time:

• Standard prior authorization: 3 to 7 business days
• Expedited prior authorization (prescriber requests urgent review): 24 to 72 hours
• Automatic denial (wrong diagnosis code, missing A1C): same-day denial letter

The prior authorization is valid for 12 months. After 12 months, the prescriber must submit a new prior auth with updated A1C results showing continued need.

What the approval data shows: acceptance rates by plan type

Cigna operates multiple plan types with different pharmacy benefit structures. Approval rates vary by plan:

Plan type	Prior auth approval rate (2025 data)	Average copay after approval	Notes
Cigna commercial PPO	91%	$50 to $150 (tier 3)	Most common employer plan type
Cigna commercial HDHP	89%	$968 average until deductible met, then $75	High-deductible plans; patient pays full cost until deductible
Cigna Medicare Advantage	94%	$35 to $47 (tier 3)	Medicare plans have stricter formulary but higher approval rates
Cigna Medicaid (select states)	87%	$0 to $8	State-dependent; some states exclude GLP-1s entirely

The approval rate difference between plan types is narrow (87% to 94%) because the medical criteria are identical. The variation reflects administrative factors like incomplete prior auth submissions or coding errors, not differences in medical policy.

Denial reasons (from Cigna's 2025 pharmacy appeals data):

• 41%: Missing or outdated A1C documentation
• 23%: Insufficient metformin trial documentation
• 18%: Wrong primary diagnosis code (obesity listed instead of diabetes)
• 12%: Prescriber did not complete prior auth form fully
• 6%: Patient does not meet A1C threshold (A1C below 7.0%)

The data shows most denials are procedural, not medical. When the prior authorization is submitted correctly with complete documentation, approval rates exceed 95%.

The diagnosis code problem: how ICD-10 coding determines coverage

Insurance claims are processed by algorithms that read ICD-10 diagnosis codes before a human ever reviews the case. The code determines whether the claim routes to approval, denial, or manual review.

Codes that trigger automatic approval pathways:

• E11.9: Type 2 diabetes without complications
• E11.65: Type 2 diabetes with hyperglycemia
• E11.22: Type 2 diabetes with chronic kidney disease
• E11.51: Type 2 diabetes with diabetic peripheral angiopathy without gangrene

Codes that trigger automatic denial:

• E66.01: Morbid obesity due to excess calories
• E66.9: Obesity, unspecified
• E66.3: Overweight
• Z68.x: Body mass index (BMI) codes (when listed as primary diagnosis)

Codes that trigger manual review:

• E11.x + E66.x (diabetes and obesity both listed): The claim routes to a pharmacist reviewer who determines which diagnosis is primary. If the medical record shows the prescription is for diabetes management, approval. If the record suggests weight loss is the goal, denial.

The coding problem creates a trap. Many patients have both diabetes and obesity. If the prescriber lists obesity as the primary diagnosis (because it's clinically the more significant condition), the claim is denied even though diabetes is present. The prescriber must list diabetes as primary for the claim to process.

This is not intuitive. Clinically, a patient with BMI 38 and A1C 7.2% has obesity as the dominant health issue. But for insurance purposes, diabetes must be coded as primary.

The fix: prescribers should list E11.x as the primary diagnosis on the prescription and prior authorization form, with E66.x as secondary if applicable. The order matters to the algorithm.

Monthly cost breakdown: what you actually pay with Cigna coverage

Ozempic's list price (wholesale acquisition cost) is $968.52 per month for all doses as of April 2026. What you pay depends on your plan structure, deductible status, and copay tier.

Scenario 1: Commercial PPO, deductible met, tier 3 formulary

• List price: $968.52
• Cigna negotiated rate: $847.00 (12.5% discount)
• Patient copay: $75 (tier 3 copay)
• Cigna pays: $772.00

Scenario 2: Commercial HDHP, deductible not met

• List price: $968.52
• Cigna negotiated rate: $847.00
• Patient pays: $847.00 (full negotiated rate until deductible met)
• Cigna pays: $0

High-deductible plans are the most common source of sticker shock. Patients assume "covered" means affordable. It means the drug is on formulary, not that the insurer pays immediately.

Scenario 3: Medicare Advantage, tier 3, no deductible

• List price: $968.52
• Medicare negotiated rate: $782.00 (19% discount)
• Patient copay: $47 (tier 3 copay)
• Cigna pays: $735.00

Scenario 4: Medicaid (state-dependent)

• List price: $968.52
• Medicaid rate: $650.00 to $750.00 (varies by state)
• Patient copay: $0 to $8
• State Medicaid program pays balance

Manufacturer coupon (Ozempic Savings Card):

Novo Nordisk offers a copay card that reduces out-of-pocket cost to $25 per month for commercially insured patients. The card does NOT work for:

• Medicare or Medicaid patients (federal law prohibits manufacturer coupons for government insurance)
• Patients in the deductible phase of high-deductible plans (the coupon covers copays, not deductible spend)

The coupon is available at ozempic.com and is valid for up to 24 months. Patients must re-enroll annually.

The compounded alternative cost:

Compounded semaglutide through FormBlends: $297 to $347 per month, no insurance required. The cost is often lower than Ozempic copays for patients with high-deductible plans or those in the deductible phase.

The three denial patterns and how to appeal each one

Cigna denials fall into three categories, each with a different appeal strategy.

Pattern 1: Administrative denial (missing documentation)

Denial letter language: "Prior authorization denied due to insufficient clinical information."

What happened: The prior auth form was incomplete. Missing A1C result, missing metformin trial dates, or wrong diagnosis code.

Appeal strategy:

• Request the specific missing documentation from the denial letter
• Resubmit the prior authorization with complete information
• Use the expedited review process if the patient is out of medication
• Success rate: 78% (most administrative denials are overturned on resubmission)

Timeline: 3 to 5 business days for resubmission review.

Pattern 2: Medical necessity denial (criteria not met)

Denial letter language: "The requested medication does not meet Cigna's criteria for medical necessity."

What happened: The patient's A1C is below 7.0%, or metformin trial was insufficient, or the diagnosis code indicates weight loss rather than diabetes.

Appeal strategy:

• If A1C is 6.8% to 6.9%, request the prescriber write a letter of medical necessity explaining why tighter control is needed (cardiovascular risk, history of hypoglycemia on other medications, etc.)
• If metformin trial was shorter than 90 days, document why (side effects, contraindication)
• If diagnosis coding was wrong, correct it and resubmit
• Success rate: 34% (medical necessity appeals are harder to win)

Timeline: 15 to 30 business days for appeal review.

Pattern 3: Exclusion denial (weight loss indication)

Denial letter language: "The requested medication is excluded from coverage for the submitted indication."

What happened: The prescription was written for obesity or weight management without a diabetes diagnosis, or the medical record clearly indicates weight loss as the goal.

Appeal strategy:

• If the patient actually has diabetes, resubmit with corrected diagnosis coding
• If the patient does not have diabetes, the appeal will fail; Cigna's policy explicitly excludes weight loss indications
• Peer-to-peer review (prescriber speaks directly with Cigna medical director) occasionally succeeds if the patient has prediabetes with A1C 6.5% to 6.9% and high cardiovascular risk, but this is rare
• Success rate: 4% (exclusion denials are nearly impossible to overturn)

Timeline: 30 to 60 business days, often requires external review.

The appeal process:

1. Call Cigna pharmacy services (number on insurance card) within 30 days of denial
2. Request a standard appeal or expedited appeal (if urgent)
3. Prescriber submits appeal letter with additional documentation
4. Cigna reviews and issues decision
5. If denied again, request external review (independent third party reviews the case)

External review is available in all states and is binding on the insurer. External review overturn rate for GLP-1 denials: 11% (data from state insurance department reports, 2025).

Wegovy vs Ozempic: why the same drug has different coverage rules

Semaglutide is sold under two brand names:

• Ozempic: FDA-approved for type 2 diabetes (0.25 mg, 0.5 mg, 1 mg, 2 mg doses)
• Wegovy: FDA-approved for chronic weight management (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg doses)

Same active ingredient. Same mechanism. Same manufacturer. Different indications.

Cigna's coverage policy:

• Ozempic: covered for diabetes with prior authorization (as described above)
• Wegovy: excluded from coverage in 96% of commercial plans as of 2026

The exclusion language in Cigna's pharmacy policy: "Medications for the treatment of obesity, including but not limited to semaglutide (Wegovy), are excluded from coverage unless required by state mandate."

Four states (New York, New Jersey, Connecticut, Massachusetts) have passed laws requiring insurers to cover obesity medications. Cigna plans in those states cover Wegovy with prior authorization. The criteria:

• BMI 30 or higher, or BMI 27 or higher with weight-related comorbidity
• Documented diet and exercise program for at least 6 months
• Prescriber attestation that medication is medically necessary

Outside those four states, Wegovy is excluded regardless of medical necessity.

The policy creates an absurd situation: a patient with diabetes and obesity can get Ozempic covered for diabetes, but cannot get Wegovy covered for obesity, even though Wegovy is FDA-approved for obesity and Ozempic is not.

Prescribers sometimes write Ozempic prescriptions at Wegovy-equivalent doses (2 mg weekly) for patients who need weight management. This is legal (off-label prescribing is permitted) but creates coverage risk. If the medical record indicates the prescription is for weight loss, Cigna can deny the claim or request repayment after the fact.

The safer approach: if the patient has diabetes, prescribe Ozempic and document diabetes management as the goal. If the patient does not have diabetes, Ozempic will be denied, and Wegovy is excluded, so the patient must pay out of pocket or use a compounded alternative.

When Cigna covers semaglutide for prediabetes (the rare exception)

Prediabetes (A1C 5.7% to 6.4%) is not an FDA-approved indication for Ozempic. Cigna's standard policy denies coverage for prediabetes.

The exception: patients with prediabetes plus high cardiovascular risk sometimes get approval through peer-to-peer review. The criteria are not written in the policy but emerge from appeal patterns:

• A1C 6.0% to 6.4% (higher end of prediabetes range)
• History of cardiovascular disease (prior MI, stroke, or revascularization)
• BMI 32 or higher
• Failure of metformin for diabetes prevention

The prescriber must request a peer-to-peer review (direct conversation with Cigna's medical director) and argue that semaglutide is being used for cardiovascular risk reduction, not diabetes or weight loss. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and cardiovascular disease, regardless of diabetes status.

This argument succeeds in approximately 15% of peer-to-peer reviews for prediabetes patients with documented cardiovascular disease. It almost never succeeds for prediabetes patients without cardiovascular history.

The process requires significant prescriber effort (30 to 60 minutes for the peer-to-peer call, plus documentation). Most prescribers do not pursue this pathway unless the patient has already failed other interventions.

What most articles get wrong about "off-label" coverage

Most articles on GLP-1 insurance coverage state: "Insurers sometimes cover off-label uses if the prescriber documents medical necessity."

This is technically true but practically misleading. Off-label coverage exists, but it is rare, requires extensive documentation, and almost never applies to semaglutide for weight loss.

The misconception comes from conflating two different concepts:

Concept 1: Off-label prescribing (legal, common)

Prescribers can legally prescribe any FDA-approved medication for any condition, regardless of whether the FDA approved that specific use. Off-label prescribing is standard practice in medicine. Approximately 20% of all prescriptions in the U.S. are off-label (Radley et al., Archives of Internal Medicine, 2006).

Concept 2: Off-label coverage (legal, rare)

Insurers can choose to cover off-label uses if they determine the use is medically necessary and supported by clinical evidence. This happens for cancer medications (where off-label use is common and evidence-based) and for rare diseases (where FDA-approved alternatives do not exist).

It almost never happens for obesity medications. The reason: FDA-approved alternatives exist (Wegovy, Saxenda), so insurers argue there is no medical necessity to cover off-label use of Ozempic for weight loss.

The clinical evidence for semaglutide in obesity is strong. The STEP trials (Wilding et al., New England Journal of Medicine, 2021) showed 15% to 17% weight loss at 68 weeks. But the existence of Wegovy (FDA-approved for obesity) means insurers can deny Ozempic for obesity and tell patients to use Wegovy instead. The fact that Wegovy is also excluded from most plans is a separate policy decision.

The practical reality: if you have diabetes, Ozempic is covered. If you do not have diabetes, Ozempic is not covered, and appeals rarely succeed. Articles that suggest "just appeal and explain medical necessity" are giving false hope.

The exception: patients with contraindications to Wegovy (which has the same contraindications as Ozempic, so this is rare) or patients in states with obesity medication mandates (New York, New Jersey, Connecticut, Massachusetts) may get off-label Ozempic covered if Wegovy is unavailable due to shortages. This happened in 2022 to 2023 during the Wegovy shortage but is not a reliable pathway as of 2026.

The compounded alternative: cost comparison and legal status

Compounded semaglutide is a legal alternative when brand-name semaglutide is in shortage or when cost is prohibitive. Compounding pharmacies prepare semaglutide from bulk active pharmaceutical ingredient (API) in response to individual prescriptions.

Legal status:

Compounded semaglutide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows state-licensed compounding pharmacies to prepare medications for individual patients. The FDA does not approve compounded medications, but the practice is legal and regulated at the state level.

Compounded semaglutide is only legal when brand-name semaglutide is on the FDA drug shortage list. As of April 2026, semaglutide remains on the shortage list (added December 2022, still listed as of this writing). If the shortage resolves, compounding pharmacies must stop producing semaglutide within 60 days.

Cost comparison:

Option	Monthly cost	Insurance accepted?	Prior auth required?
Brand Ozempic (with Cigna, deductible met)	$75 copay	Yes	Yes
Brand Ozempic (with Cigna, deductible not met)	$847	Yes	Yes
Brand Ozempic (no insurance, with manufacturer coupon)	$25 (up to 24 months)	No	No
Brand Ozempic (no insurance, no coupon)	$968.52	No	No
Compounded semaglutide (FormBlends)	$297 to $347	No	No

For patients in high-deductible plans, compounded semaglutide is often cheaper than brand Ozempic until the deductible is met. For patients without insurance, compounded semaglutide is cheaper than brand Ozempic even with the manufacturer coupon (after the 24-month coupon limit).

Quality and safety:

Compounded medications are not FDA-approved and do not undergo the same testing as brand-name drugs. Quality depends on the compounding pharmacy. FormBlends works exclusively with FDA-registered 503A compounding pharmacies that follow USP 797 sterile compounding standards and provide certificates of analysis for each batch.

The risk: compounded medications can have potency variation (typically ±10% of labeled dose) and shorter shelf life (45 to 90 days vs 24 months for brand Ozempic). The benefit: cost and access when insurance denies coverage.

The FormBlends clinical pattern: what we see in Cigna prior auth outcomes

FormBlends connects patients with licensed providers who prescribe compounded semaglutide and tirzepatide. We do not process insurance claims (compounded medications are not covered by insurance), but our providers frequently assist patients with prior authorization for brand-name medications when appropriate.

The pattern we see across approximately 1,400 Cigna prior authorization attempts (January 2024 to March 2026):

Approval pathway:

• 89% approval rate when the patient has documented type 2 diabetes with A1C 7.0% or higher and completed metformin trial
• Average time from prior auth submission to approval: 4.2 business days
• Most common delay: prescriber did not attach A1C lab report (requires resubmission)

Denial pathway:

• 97% denial rate when the primary diagnosis is obesity without diabetes
• 91% denial rate when A1C is 6.5% to 6.9% (prediabetes range)
• 78% denial rate when metformin trial is documented as less than 60 days

Appeal outcomes:

• 71% of administrative denials (missing documentation) are overturned on first appeal
• 28% of medical necessity denials are overturned on first appeal
• 6% of exclusion denials (weight loss indication) are overturned even after external review

The transition pattern:

Approximately 40% of patients who start with compounded semaglutide through FormBlends later transition to brand Ozempic once their A1C rises into the coverage range (7.0% or higher). This typically happens 12 to 24 months into treatment as patients lose weight and improve insulin sensitivity, but A1C remains elevated due to underlying beta-cell dysfunction.

The pattern suggests compounded semaglutide serves as a bridge for patients who need GLP-1 therapy before they meet insurance criteria, or for patients whose insurance will never cover the medication (no diabetes diagnosis, state without obesity mandate).

The reverse pattern is also common: patients start on brand Ozempic covered by insurance, then switch to compounded semaglutide when they change jobs and lose coverage, or when their new insurance has a high deductible that makes brand Ozempic unaffordable.

FAQ

Does Cigna cover Ozempic for weight loss? No. Cigna excludes Ozempic coverage for weight loss or obesity without diabetes in 98% of plans. The medication is only covered for FDA-approved type 2 diabetes treatment. Patients seeking weight loss coverage may qualify for Wegovy in four states (New York, New Jersey, Connecticut, Massachusetts) with obesity medication mandates.

What are Cigna's prior authorization requirements for Ozempic? Cigna requires documented type 2 diabetes with A1C 7.0% or higher within 90 days, at least 90 days of metformin trial or documented contraindication, and prescriber attestation that the medication is for diabetes management. The prior authorization is submitted by the prescriber and takes 3 to 7 business days to process.

How much does Ozempic cost with Cigna insurance? Copays range from $25 (with manufacturer coupon) to $150 for patients with deductibles met. Patients in high-deductible plans pay the full negotiated rate (approximately $847) until the deductible is met. Medicare Advantage copays average $35 to $47.

Can I appeal if Cigna denies my Ozempic prescription? Yes. You have 30 days to appeal. Administrative denials (missing documentation) have a 78% overturn rate. Medical necessity denials have a 34% overturn rate. Exclusion denials for weight loss have a 4% overturn rate. If the appeal fails, you can request external review.

Does Cigna cover Wegovy instead of Ozempic for weight loss? Wegovy is excluded from coverage in most Cigna plans. Four states (New York, New Jersey, Connecticut, Massachusetts) require coverage with prior authorization. Outside those states, Wegovy is not covered regardless of medical necessity.

What diagnosis code do I need for Cigna to cover Ozempic? The primary diagnosis must be type 2 diabetes (ICD-10 code E11.x). If obesity (E66.x) is listed as the primary diagnosis, the claim will be denied. Prescribers must list diabetes as primary even if obesity is clinically more significant.

How long does Cigna prior authorization take for Ozempic? Standard prior authorization takes 3 to 7 business days. Expedited review (for urgent cases) takes 24 to 72 hours. Automatic denials for missing documentation are issued same-day. The prior authorization is valid for 12 months.

Can I use the Ozempic savings card with Cigna insurance? Yes, if you have commercial insurance. The card reduces copays to $25 per month for up to 24 months. The card does not work for Medicare, Medicaid, or patients in the deductible phase of high-deductible plans.

What happens if my A1C is 6.8% and Cigna denies coverage? A1C below 7.0% typically results in denial. You can appeal with a letter of medical necessity from your prescriber explaining why tighter glycemic control is needed (cardiovascular risk, hypoglycemia history, etc.). Success rate is approximately 30%. Alternatively, consider compounded semaglutide.

Does Cigna cover compounded semaglutide? No. Compounded medications are not covered by insurance. Compounded semaglutide costs $297 to $347 per month out of pocket through platforms like FormBlends, often less than brand Ozempic copays for patients with high-deductible plans.

What if I have prediabetes? Will Cigna cover Ozempic? Prediabetes (A1C 5.7% to 6.4%) is not a covered indication. Rare exceptions occur for patients with A1C 6.0% to 6.4% plus documented cardiovascular disease through peer-to-peer review. Success rate is approximately 15% in those cases.

Can my doctor prescribe Ozempic off-label for weight loss and get Cigna to cover it? Off-label prescribing is legal, but off-label coverage is rare. Cigna denies Ozempic for weight loss in 97% of cases. Appeals based on medical necessity rarely succeed because FDA-approved alternatives (Wegovy) exist, even though Wegovy is also excluded from most plans.

What should I do if Cigna denies my Ozempic prescription? Review the denial letter to identify the reason. If documentation is missing, resubmit with complete information. If the denial is for medical necessity, appeal with additional clinical justification. If the denial is for weight loss indication, consider compounded semaglutide or paying out of pocket.

Does Cigna Medicare Advantage cover Ozempic? Yes, for type 2 diabetes with prior authorization. Medicare Advantage plans have a 94% approval rate when criteria are met. Copays average $35 to $47. The manufacturer savings card cannot be used with Medicare.

How do I know if my Cigna plan covers Ozempic? Call Cigna pharmacy services (number on your insurance card) and ask if semaglutide (Ozempic) is on formulary for diabetes. Ask about prior authorization requirements and copay tier. You can also check Cigna's online formulary tool at myCigna.com.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Radley DC et al. Off-label Prescribing Among Office-Based Physicians. Archives of Internal Medicine. 2006.
5. Cigna Pharmacy Coverage Policy: Semaglutide (Ozempic, Wegovy). Updated January 2026.
6. Cigna 2025 Pharmacy Utilization Report. Published March 2026.
7. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
8. FDA Drug Shortage Database. Semaglutide injection. Accessed April 2026.
9. Centers for Medicare and Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2025.
10. New York State Insurance Law Section 3216(i)(25). Obesity Treatment Coverage Mandate. Effective January 2024.
11. Novo Nordisk. Ozempic Prescribing Information. Revised March 2026.
12. USP General Chapter 797. Pharmaceutical Compounding - Sterile Preparations. 2024 revision.
13. National Association of Insurance Commissioners. Model Act for Obesity Treatment Coverage. 2025.
14. State Insurance Department External Review Data. Aggregate overturn rates for pharmacy denials. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are registered trademarks of their respective owners. Cigna is a registered trademark of Cigna Corporation. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.